HEPATOL RES 润色咨询

HEPATOLOGY RESEARCH

出版年份：1997 年文章数：1255 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：9.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2024-04-23 国统乃我辈之愿 来自海南省

    为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2024-02-10 邓医生的株式会社 来自安徽省

    审稿速度:1.0
    经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2023-08-24 ms2000000070952725 来自河南省

    投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2022-08-13 Ysbstsvshndudnd

    想咨询一下这个杂志是OA的吗？版面费大概多少？

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2022-05-14 ms1000000867109818

    这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2022-02-17 381302

    请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2020-10-27 ms9476632540558124

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：肝癌临床回顾性研究，2天秒拒。。。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2020-03-11 Liuying11

    同问，求各位大神解答155****5276暂无昵称 2020-02-16 发表::
    这个收生信的文章吗    155****5276暂无昵称 2020-02-16 00:00:00 发表:
    这个收生信的文章吗

    155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2020-02-16 1228d76am76暂无昵称

    这个收生信的文章吗

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219571, encodeId=70ed12195e17a, content=这个杂志的figure legends要单独列出来吗？不能放在图片里面吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat May 14 14:08:33 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2019-11-27 貊剑觫

    审稿速度:2.0
    经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10
    January 2019.

    0

共89条页码: 2/9页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分